The AAJT-S is targeted at reducing deaths from junctional
inguinal bleeding in accordance with the August 2011
TCCC guidelines. These bleeds continue to be a significant
source of morbidity and mortality on the battlefield. The
AAJT S provides a rapid application of pneumatic
compression to the aorta at the abdominal pelvic junction
to occlude blood flow in the inguinal arteries and also in
the axilla and other junctional areas.
The AAJT-S is FDA approved for the treatment of
junctional haemorrhages.